Banca de QUALIFICAÇÃO: MICHELLI DOS SANTOS

Uma banca de QUALIFICAÇÃO de DOUTORADO foi cadastrada pelo programa.
STUDENT : MICHELLI DOS SANTOS
DATE: 28/04/2022
TIME: 09:00
LOCAL: Remoto via plataforma Google Meet
TITLE:

Development of an immunological diagnostic kit for Schistosoma mansoni

KEY WORDS:

Schistosoma mansoni; chimeric proteins; diagnostic kits.

PAGES: 70
BIG AREA: Multidisciplinar
AREA: Biotecnologia
SUMMARY:

Schistosomiasis, a neglected tropical parasitic disease caused by the trematode worms of the genus Schistosoma, affects approximately 240 million people worldwide. Among the main species that infect humans, Schistosoma mansoni is responsible for the majority of hepato-intestinal schistosomiasis. Accurate and affordable diagnostic tools are essential to provide targeted treatment and maximize the success of schistosomiasis control in endemic areas. The diagnosis of schistosomiasis can be performed by parasitological, molecular and immunological methods. Traditional parasitological methods, such as the Kato-Katz stool egg count assay, are relatively inexpensive and easy to perform, however, a major limitation of these methods is the lack of sensitivity, especially in low-grade infections such as in low-prevalence areas or in individuals with recent infections. Molecular methods, although achieving high sensitivity and specificity, are expensive. Immunological tests are especially relevant for disease surveillance and preliminary screening in non-endemic areas, where the low sensitivity of parasitological tests can result in a false-negative diagnosis of infected individuals. In order to effectively control and monitor schistosomiasis, new diagnostic methods are essential. In this sense, given the need to develop a test with high sensitivity and specificity, this proposal tends to optimize the conditions of an immunological test (ELISA) for the diagnosis of schistosomiasis mansoni with a view to technology transfer, using the (s) chimeric protein(s) designed rationally. The present work has great potential for innovation and social impact since most of the commercial diagnostic kits used in Brazil are imported. In addition, the fact that the company Quibasa (Bioclin), co-proponent of this project, does not yet have a commercial diagnostic kit for schistosomiasis, confirms the great magnitude of the project. Thus, the chimeric proteins that are the focus of this work are of great interest to the company to optimize a commercial diagnostic kit that can complement current diagnostic methods.

BANKING MEMBERS:
Presidente - 1367304 - ALEXSANDRO SOBREIRA GALDINO
Externa ao Programa - 2059999 - MARIANA CAMPOS DA PAZ LOPES GALDINO
Externa à Instituição - MARIA DE LOURDES BORBA MAGALHÃES - UDESC
Externo à Instituição - SORAYA DOS SANTOS PEREIRA - FIOCRUZ